Literature DB >> 12672204

Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia.

Jennifer S McCall-Hosenfeld1, Don L Goldenberg, Shelley Hurwitz, Gail K Adler.   

Abstract

OBJECTIVE: To determine activity of the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis in women with fibromyalgia (FM).
METHODS: Premenopausal women with FM (n = 24) and premenopausal healthy women (n = 27) were studied. IGF-1 was measured in 23 patients with FM and 25 controls. GH was measured during a stepped hypoglycemic hyperinsulinemic clamp procedure (blood glucose decreased from 90 to 40 mg/dl every 30 min in 10 mg/dl decrements) in 12 FM and 13 control subjects.
RESULTS: IGF-1 concentrations were similar in the FM (200 +/- 71 ng/ml, mean +/- SD) and control (184 +/- 70 ng/ml) groups. By multiple variable analysis, IGF-1 was negatively associated with age (p = 0.0006), body mass index (BMI) (p = 0.006), and 24 h urinary free cortisol (p = 0.007) in healthy controls. Even after accounting for these factors, there was no association between FM and IGF-1. The average peak GH achieved during hypoglycemia was lower in patients with FM (range 5 to 58 ng/ml, median 13 ng/ml) versus controls (6 to 68 ng/ml, median 21 ng/ml) (p = 0.04). However, BMI was a significant predictor of average peak GH in FM (r = -0.62, p < 0.01) and control subjects (r = -0.40, p = 0.06). After considering BMI, there was no significant association between FM subjects and the average peak GH (p = 0.20).
CONCLUSION: In this sample of premenopausal women with FM, the activity of the GH-IGF-1 axis was similar to that of healthy controls. Increases in age and obesity were both strongly associated with lower activity of this axis, suggesting that these factors must be considered when studying activity of the GH-IGF-1 axis in FM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672204

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  [Etiology and pathophysiology of fibromyalgia syndrome and chronic widespread pain].

Authors:  C Sommer; W Häuser; K Gerhold; P Joraschky; F Petzke; T Tölle; N Uçeyler; A Winkelmann; K Thieme
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

Review 2.  Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis.

Authors:  B Abbi; B H Natelson
Journal:  QJM       Date:  2012-08-26

Review 3.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

Review 4.  GH/IGF1 axis disturbances in the fibromyalgia syndrome: is there a rationale for GH treatment?

Authors:  G Cuatrecasas; C Alegre; F F Casanueva
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

Review 5.  Fibromyalgia: A Critical and Comprehensive Review.

Authors:  Andrea T Borchers; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

Review 6.  Growth hormone in musculoskeletal pain states.

Authors:  Robert Bennett
Journal:  Curr Pain Headache Rep       Date:  2005-10

7.  Glucose tolerance in fibromyalgia.

Authors:  Teemu Zetterman; Ritva Markkula; Eija Kalso
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

8.  Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study.

Authors:  Guillem Cuatrecasas; Cristina Riudavets; Maria Antònia Güell; Albert Nadal
Journal:  BMC Musculoskelet Disord       Date:  2007-11-30       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.